C-Rad has completed a directed new share issue providing the company with proceeds of approximately SEK 108 million before deduction of transaction costs.

C-Rad develops innovative solutions for use in advanced radiation therapy. The net proceeds from the transaction will primarily be used to support the company’s growth, which includes investments in expanding C-Rad’s product portfolio to increase efficiency and safety within radiation therapy.

Investors in the transaction are a number of Swedish and international institutional investors, including TIN Fonder, Joh. Berenberg, Gossler & Co. KG (Berenberg), Humle Småbolagsfond and Alfred Berg Kapitalförvaltning.

Pareto Securities is acting as sole manager and bookrunner and Baker McKenzie is legal adviser to C-Rad in connection with the transaction. Baker McKenzie's team consists of Joakim Falkner, Ian Gulam and Per Blom.

Explore Our Newsroom